Levocetirizine + Montelukast Syrup

Project Image
Thumb Image
Thumb Image
Thumb Image
Thumb Image

Therapeutic Indication

Allergic rhinitis
Respiratory hypersensitivity conditions
Sneezing and runny nose
Nasal congestion
Seasonal allergies
Allergic cough
+91 85919 78885

Levocetirizine + Montelukast

Syrup

Levocetirizine + Montelukast Syrup is an anti-allergic combination formulation used for the management of allergic rhinitis, sneezing, runny nose, nasal congestion, and allergic respiratory conditions.
Levocetirizine helps block histamine-mediated allergic reactions, while Montelukast works by inhibiting leukotrienes, substances responsible for airway inflammation, allergy symptoms, and bronchial irritation. Together, they provide effective relief from seasonal allergies and respiratory hypersensitivity.
This combination is commonly used in pediatric and adult patients to improve breathing comfort and reduce recurrent allergic symptoms.

Speciality Allergy Care | Respiratory Care
Tags Anti-Allergic | Antihistamine | Leukotriene Antagonist | Pediatric Care
Strength
  • Levocetirizine – 2.5 mg / 5 ml
  • Montelukast – 4 mg / 5 ml
Packing Size
  • 60 ml Bottle

Check all Tablet Range

Click to know More

Mechanism

Levocetirizine: Selectively blocks H1 histamine receptors, reducing allergic symptoms such as sneezing, itching, and nasal discharge.
Montelukast: Blocks leukotriene receptors, helping reduce airway inflammation, mucus production, and allergic respiratory symptoms.

Benefits

  • Provides relief from allergy symptoms
  • Reduces sneezing and nasal irritation
  • Supports easier breathing in allergic conditions
  • Reduces airway inflammation and congestion
  • Suitable for pediatric and adult use under medical supervision

Side Effects

  • Dry Mouth
  • Headache
  • Fatigue

Pharmacokinetics

  • Levocetirizine:
  • Absorption: Rapid, peak plasma ~1 hour,
  • Bioavailability: ~100%
  • Excretion: Mainly unchanged via urine
  • Half‑life: ~7–10 hours

  • Montelukast:
  • Absorption: Rapid, peak plasma ~3–4 hours,
  • Bioavailability: ~64%
  • Metabolism: Extensive hepatic (CYP3A4, CYP2C9) .
  • Excretion: Mostly via bile/feces
  • Half‑life: ~2.7–5.5 hours

Contraindication

  • Hypersensitivity to Levocetirizine, Montelukast, or related compounds
  • Severe renal impairment (use with caution)

Dosage

  • As directed by the physician.

INTERACTIONS

  • CNS depressants: May increase drowsiness
  • Phenobarbital and rifampicin: May reduce Montelukast effectiveness
  • Alcohol: May enhance sedative effects

Warning and Precautions

    This has been prescribed for the patient's specific condition. It may be dangerous to any other person.

  • Use cautiously in patients with liver disorders
  • May cause mild drowsiness in some individuals
  • Use during pregnancy or lactation only under medical advice
  • Do not exceed recommended dosage
  • Store in a cool, dry place away from direct sunlight
  • Keep out of reach of children

Disclaimer

All product details on this website are for reference and informational purposes only and are not directed at patients or consumers.
As a contract manufacturer, DM Pharma Pvt Ltd is not responsible for the marketing or end use of these products and disclaims all liability arising from reliance on this information.
Please consult a healthcare professional before using any medicinal product.